CNTGF (Centogene NV) ROCE %: -31.59% (As of Dec. 2023)


CNTGF Centogene NV CNTGF
12 GF Score
Price $0.12
View Full Analysis

What is Centogene NV ROCE %?

Centogene NV CNTGF 12 ROCE % is -31.59% as of Dec. 2023. GuruFocus rates CNTGF with a GF Score™ of 12/100.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Centogene NV's annualized ROCE % for the quarter that ended in Dec. 2023 was -31.59%.

Centogene NV  (OTCPK:CNTGF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Centogene NV ROCE % Related Terms

Centogene NV ROCE % Historical Data

* Premium members only.

The historical data trend for Centogene NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Centogene NV ROCE % Chart

Centogene NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROCE %
Get a 7-Day Free Trial -26.26 -67.72 -74.68 -56.81 -54.10

Centogene NV Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.33 -64.61 -45.25 -74.70 -31.59
CNTGF
12GF Score
Centogene NV CNTGF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Centogene NV ROCE % Calculation

Centogene NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-29.492/( ( (98.318 - 26.128) + (84.138 - 47.291) )/ 2 )
=-29.492/( (72.19+36.847)/ 2 )
=-29.492/54.5185
=-54.10 %

Centogene NV's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2023 )  (Q: Jun. 2023 )(Q: Dec. 2023 )
=-13.518/( ( (77.889 - 29.146) + (84.138 - 47.291) )/ 2 )
=-13.518/( ( 48.743 + 36.847 )/ 2 )
=-13.518/42.795
=-31.59 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -31.59% mean?
Centogene NV (CNTGF) has a ROCE % of -31.59% as of Dec. 2023.
Is Centogene NV's ROCE % too high?
Centogene NV's current ROCE % is -31.59%. Overall, Centogene NV has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Centogene NV's ROCE % compare to ISPC and CHEK?
Centogene NV's ROCE % of -31.59% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Diagnostics & Research company?
A good ROCE % depends on the Medical Diagnostics & Research industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Centogene NV's current ROCE % is -31.59%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Centogene NV stock overvalued right now?
Centogene NV (CNTGF) has a current ROCE % of -31.59%. The current ROCE % is -31.59%. Centogene NV's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Centogene NV (CNTGF), the current ROCE % is -31.59% as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Centogene NV Business Description

Address Am Strande 7, Rostock, MV, DEU, 18055
Centogene NV is a United States-based company engaged in data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. The company operates in two segments: pharmaceutical and diagnostics. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its diagnostics segment provides targeted genetic sequencing and diagnostics services to patients. Its geographic regions are Europe, the Middle East, North America, and Latin America.
12GF Score

Get the complete analysis for CNTGF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price